ClinicalTrials.gg
RecruitingNCT07881887Updated Nov 18, 2026

A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes

A Phase 1 interventional study of LY4167586 and Placebo in Obesity, Overweight and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Recruiting at 15 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
617
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 118 studies in Obesity by Eli Lilly and Company — 30 open to participants now, 54 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Planned enrollment
30th of 117
617 · median 267
Started
2026
with 24 others
Phase 1
40 of 118
8 open now
Primary completion
2029-03
later than 47 of 53 live
Registered
115th of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 30th largest by planned enrollment of the 117 interventional ones that give a count, is one of 25 that started in 2026, is one of 40 in phase 1, reaches primary completion later than 47 of the 53 other live ones, and was the 115th registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

30 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.

Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.

03

Conditions studied

  • Obesity
  • Overweight
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 21 in Singapore.
  • Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent (%) body weight change.

Part A, B, D, and E

  • Have a (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:

    • hypertension
    • dyslipidemia
    • obstructive sleep apnea, or
    • prediabetes.

Part C

  • Have a BMI ≥25.0 kg/m²
  • Have a diagnosis of Type 2 Diabetes (T2D) for at least 6 months.
  • T2D controlled with diet and exercise alone or are on a stable dose of metformin alone, or in combination with a sodium-glucose co-transporter-2 inhibitor (SGLT-2i), for at least 3 months.
  • Have a () value of ≥6.5 % and ≤10.0%.

Part D

  • To qualify as Chinese for this study, the participant must be at a minimum third-generation Chinese, defined as having all 4 of the participants' biological grandparents being of exclusive Chinese descent and born in China.

Part E

  • To qualify as Japanese for this study, the participant must be at a minimum third-generation Japanese, defined as having all 4 of the participants' biological grandparents being of exclusive Japanese descent and born in Japan.

Exclusion criteria

Exclusion Criteria:

  • Have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine (except for T2D in Part C), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
617 participants (estimated)

Study arms

  • Experimental
    Part A: LY4167586

    LY4167586 administered subcutaneously (SC)

    Drug: LY4167586

  • Experimental
    Part B LY4167586

    LY4167586 administered SC

    Drug: LY4167586

  • Experimental
    Part C LY4167586

    LY4167586 administered SC

    Drug: LY4167586

  • Experimental
    Part D LY4167586

    LY4167586 administered SC

    Drug: LY4167586

  • Experimental
    Part E LY4167586

    LY4167586 administered SC

    Drug: LY4167586

  • Placebo comparator
    Placebo (Part A-E)

    Placebo administered SC

    Drug: Placebo

Interventions

  • DrugLY4167586

    administered SC

  • DrugPlacebo

    administered SC

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline through Study Completion (Estimated as Week 89)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4167586

    Time frame: Baseline up to Week 89

  2. PK: Area Under the Concentration Time Curve (AUC) of LY4167586

    Time frame: Baseline up to Week 89

  3. Body Weight Observed Value

    Time frame: Baseline up to Week 89

  4. Change from Baseline in Body Weight

    Time frame: Baseline up to Week 89

  5. Percent Change from Baseline in Body Weight

    Time frame: Baseline up to Week 89

07

Study locations

12 of 15 sites recruiting
  • Woodland Research Northwest, LLC
    Rogers, Arkansas 72758, United States
    Not yet recruiting
    • · Contact479-927-3000
    • Timothy Cook · Principal investigator
  • CenExel ACT
    Anaheim, California 92801, United States
    Recruiting
    • Amina Haggag · Principal investigator
  • Collaborative Neuroscience Network - CNS
    Los Alamitos, California 90720, United States
    Recruiting
    • Steven Reynolds · Principal investigator
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
    Recruiting
    • Bonnie Kimmel · Principal investigator
  • Fortrea Clinical Research Unit
    Daytona Beach, Florida 32117, United States
    Recruiting
    • · Contact866-429-3700
    • Chiamaka Iheme · Principal investigator
  • Advanced Pharma CR, LLC
    Miami, Florida 33417, United States
    Not yet recruiting
    • Simon Abelson · Principal investigator
  • Clinical Site Partners, LLC DBA CSP Orlando
    Winter Park, Florida 32789, United States
    Recruiting
    • ROBERT MEYER · Principal investigator
  • Centricity Research
    Columbus, Georgia 31904, United States
    Recruiting
    • · Contact706-321-0495
    • Joseph Surber · Principal investigator
  • CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
    Recruiting
    • Kimball Johnson · Principal investigator
  • QPS
    Springfield, Missouri 65802, United States
    Recruiting
    • · Contact417-893-6161
    • Leea Reed · Principal investigator
  • CenExel-HRI
    Marlton, New Jersey 08053, United States
    Recruiting
    • Kyle Coupe · Principal investigator
  • Ohio Clinical Trials
    Columbus, Ohio 43212, United States
    Recruiting
    • Angela Eakin · Principal investigator
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
    Recruiting
    • Archie Bowie · Principal investigator
  • Worldwide Clinical Trials, Inc.
    San Antonio, Texas 78217, United States
    Recruiting
    • Alan Hand · Principal investigator
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
    Not yet recruiting
    • · Contact64139811
    • Jennifer Boon Wee · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2029, 29 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 29 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Oct 20, 2026
StartActual
Oct 22, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
3 sites added. 12 sites changed recruiting status (10 now recruiting, 2 now not yet recruiting)
Show 12 sites
  • CenExel ACT · Anaheim, United Statesno status→Recruiting
  • Collaborative Neuroscience Network - CNS · Los Alamitos, United Statesno status→Recruiting
  • Diablo Clinical Research, Inc. · Walnut Creek, United Statesno status→Recruiting
  • Fortrea Clinical Research Unit · Daytona Beach, United Statesno status→Recruiting
  • Advanced Pharma CR, LLC · Miami, United Statesno status→Not yet recruiting
  • Clinical Site Partners, LLC DBA CSP Orlando · Winter Park, United Statesno status→Recruiting
  • CenExel iResearch, LLC · Decatur, United Statesno status→Recruiting
  • CenExel-HRI · Marlton, United Statesno status→Recruiting
  • Ohio Clinical Trials · Columbus, United Statesno status→Recruiting
  • Fortrea Clinical Research Unit · Dallas, United Statesno status→Recruiting
  • Worldwide Clinical Trials, Inc. · San Antonio, United Statesno status→Recruiting
  • Lilly Centre for Clinical Pharmacology · Singapore, Singaporeno status→Not yet recruiting
Show 3 added (3 United States)
  • Woodland Research Northwest, LLC · Rogers, United States
  • Centricity Research · Columbus, United States
  • QPS · Springfield, United States
Nov 18, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Fortrea Clinical Research Unit · Dallas, United StatesContact removed •••3700
Nov 18, 2026
Registered
First appeared on the registry
Oct 20, 2026
Show all 2 updates
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    3 sites added. 12 sites changed recruiting status (10 now recruiting, 2 now not yet recruiting)
    Show 12 sites
    • CenExel ACT · Anaheim, United Statesno status→Recruiting
    • Collaborative Neuroscience Network - CNS · Los Alamitos, United Statesno status→Recruiting
    • Diablo Clinical Research, Inc. · Walnut Creek, United Statesno status→Recruiting
    • Fortrea Clinical Research Unit · Daytona Beach, United Statesno status→Recruiting
    • Advanced Pharma CR, LLC · Miami, United Statesno status→Not yet recruiting
    • Clinical Site Partners, LLC DBA CSP Orlando · Winter Park, United Statesno status→Recruiting
    • CenExel iResearch, LLC · Decatur, United Statesno status→Recruiting
    • CenExel-HRI · Marlton, United Statesno status→Recruiting
    • Ohio Clinical Trials · Columbus, United Statesno status→Recruiting
    • Fortrea Clinical Research Unit · Dallas, United Statesno status→Recruiting
    • Worldwide Clinical Trials, Inc. · San Antonio, United Statesno status→Recruiting
    • Lilly Centre for Clinical Pharmacology · Singapore, Singaporeno status→Not yet recruiting
    Show 3 added (3 United States)
    • Woodland Research Northwest, LLC · Rogers, United States
    • Centricity Research · Columbus, United States
    • QPS · Springfield, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Fortrea Clinical Research Unit · Dallas, United StatesContact removed •••3700
    + 2 other changes: verification date and date precision
  2. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07881887
Responsible party
Sponsor
First posted
Oct 20, 2026
Start date
Oct 22, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion